Table 1 Patient demographics and their clinical characteristics

From: t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs

Characteristics

t(14;16) Positive, n=35

t(14;16) Negative, n=124

P valuea

Age, years, median (range)

64 (36–86)

69 (34–95)

0.137

Sex

 Male

12/35 (34%)

53/124 (43%)

0.369

ECOG PS b

 2–4

6/32 (19%)

33/124 (27%)

0.360

ISS

 Stage

23/34 (68%)

53/119 (45%)

0.017

M protein

 IgG

27/35 (77%)

54/124 (44%)

<0.001c

IgA

2/35 (6%)

29/124 (23%)

 

IgD

0/35 (0%)

7/124 (7%)

 

Othersd

6/35 (17%)

34/124 (26%)

 

Light chain

 κ

17/35 (49%)

75/124 (60%)

0.208

Bone lesion

 Positive

23/35 (66%)

84/108 (78%)

0.153

Upfront ASCT

 Yes

8/35 (23%)

34/124 (27%)

 

Novel drugs e

 Yes

31/35 (86%)

90/124 (73%)

 

Bone marrow laboratory results

 FISH

c-MAF

35/35 (100%)

−

 

 G-band

t(14;16)

7/30 (23%)

−

 

Abnormalf

16/30 (53%)

19/123 (15%)

<0.001

 CD20

Positive (⩾20%)

11/23 (48%)

15/110 (14%)

<0.001

 CD56

Positive (⩾20%)

0/23 (0%)

79/111 (71%)

<0.001

Peripheral blood laboratory

 WBC

>10 000/μl

6/35 (17%)

1/124 (1%)

<0.001

 PB involvementg

Positive

10/35 (29%)

24/118 (20%)

0.304

 Hbh

<8.5 g/dl

15/35 (43%)

40/124 (32%)

0.244

 PLT

<100 × 103/μl

12/35 (34%)

7/124 (6%)

<0.001

 cCai

>11 mg/dl

2/35 (6%)

30/124 (24%)

0.016

 Total protein

⩾10.0 g/dl

18/35 (51%)

29/124 (23%)

0.001

 Albumin

<3.5 g/dl

16/19 (46%)

70/124 (56%)

0.260

 LDH

>1.0Nj

9/35 (26%)

25/123 (20%)

0.494

 β2-microglobulin

⩾5.5 mg/l

21/34 (62%)

53/118 (45%)

0.083

 Creatinine

>2.0 mg/dl

30/35 (86%)

101/124 (81%)

0.559

  1. Abbreviations: ASCT, autologous stem cell transplantation; c-MAF, c-musculoaponeurotic fibrosarcoma; ECOG, Eastern Cooperative Oncology Group; FISH, fluorescence in situ hybridization; ISS, international staging system; LDH, lactate dehydrogenase; PLT, platelet count; PS, performance status; WBC, white blood cells.
  2. aP values were calculated using the χ2 test except CD56, WBC and cCa being calculated using the Fisher's exact test. Age was calculated using the Mann–Whitney U-test.
  3. bPS proposed by ECOG.
  4. cP value was calculated for IgG and non-IgG types.
  5. dIncluding the IgM, IgD and BJP types.
  6. eOne or more lines of novel drugs; Bortezomib, Thalidomide and Lenalidomide.
  7. fGenetic aberration without t(14;16).
  8. gPeripheral blood involvement of myeloma cells.
  9. hHemoglobin.
  10. iCompensation calcium value.
  11. j1.0 N means the upper limit of the normal range at each institution.
Back to article page